Streetbeat News

NYXH

Nyxoah S.A.

https://www.nyxoah.com

Industry

Medical - Instruments & Supplies

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Cantor Fitzgerald analyst Ross Osborn maintains an Overweight rating on Nyxoah (NASDAQ:NYXH) but lowers the price target from $17 to $16.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 5:58 pm

HC Wainwright & Co. analyst Edward White has reiterated a Buy rating on Nyxoah (NASDAQ:NYXH) and maintained a price target of $18.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 12:24 pm

Oppenheimer analyst Suraj Kalia maintains an Outperform rating on Nyxoah (NASDAQ:NYXH) but lowers the price target from $15 to $13.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 11:58 am

Nyxoah (NASDAQ:NYXH) reported Q2 2024 GAAP EPS of $(0.46), missing the $(0.40) estimate by 15%. Sales were $830.066K, missing the $1.798M estimate by 53.83% and down 31.23% from last year's $1.207M.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 8:54 pm

Nyxoah announced that it has signed a €37.5M loan facility agreement with the European Investment Bank.

Portfolio Pulse from Benzinga Newsdesk

July 03, 2024 | 10:31 am

Nyxoah has submitted the final module of its Premarket Approval (PMA) application for its innovative sleep apnea treatment, Genio, to the FDA. Genio is a unique hypoglossal nerve stimulation (HGNS) solution that is leadless, fully-body MRI compatible, and powered by a wearable device. The DREAM U.S. pivotal study data showed significant improvements in sleep apnea metrics.

Portfolio Pulse from Benzinga Newsdesk

July 01, 2024 | 6:52 am

Stifel analyst Jonathan Block maintains a Buy rating on Nyxoah (NASDAQ:NYXH) but lowers the price target from $27 to $19.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 12:58 pm

Nyxoah has completed a $50M offering and subsequent sale of additional shares, raising a total of $52.5M. The funds will be used for pre-commercialization and commercialization activities in the US, clinical research, R&D for the Genio system, and other corporate purposes.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 7:15 am

HC Wainwright & Co. has maintained a Buy rating on Nyxoah (NASDAQ:NYXH) but lowered the price target from $22 to $18.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2024 | 11:00 am

Nyxoah shares are trading lower following the announcement of a $50 million public offering, pricing 5,374,755 shares at $9.25 per share.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2024 | 4:37 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.